Mangoceuticals (NASDAQ: MGRX) Announces Transformative Business Combination with Nuclea Energy Inc.
Key Strategic Move Positions Company for Entry into Advanced Nuclear Energy Markets Amid Surging AI and Data Center Power Demand
DALLAS, TEXAS – July 30, 2026 – Mangoceuticals, Inc. (“Mangoceuticals” or the “Company”) has entered into a definitive business combination agreement with Nuclea Energy Inc. (“Nuclea”), an advanced nuclear technology company developing the Morpheus lead-cooled microreactor. This transaction marks a dramatic strategic shift for Mangoceuticals, providing the Company and its shareholders with exposure to the burgeoning advanced nuclear sector as the demand for reliable, carbon-free electricity rises sharply due to artificial intelligence (AI) infrastructure, hyperscale data centers, electrification, and the reshoring of domestic manufacturing.
Key Highlights of the Agreement
- Definitive Business Combination Structure: A newly formed Mangoceuticals subsidiary will amalgamate with Nuclea, making Nuclea an indirect wholly owned subsidiary. Nuclea shareholders will receive exchangeable shares in a Mangoceuticals subsidiary, which are exchangeable on a one-for-one basis for Mangoceuticals common stock. These shares carry economic and voting rights substantially equivalent to Mangoceuticals common stock, subject to a Nasdaq-mandated cap.
- Nasdaq Cap Limitation: Until Mangoceuticals obtains both stockholder and Nasdaq approval, the economic, voting, and exchange rights attributable to these exchangeable shares and any new Mangoceuticals stock issued in the transaction will be limited to 19.99% of the outstanding common stock prior to closing. No shareholder can exceed this cap until approvals are received.
- Board Approval and Next Steps: The Boards of both companies have approved the transaction. Completion requires Mangoceuticals stockholder approval due to the number of shares to be issued. Mangoceuticals will file a Form S-4 registration statement with the SEC, including a proxy statement for shareholder approval.
Strategic Rationale and Growth Drivers
- Massive Increase in Power Demand: U.S. electricity demand is expected to rise rapidly, driven by AI, hyperscale data centers, electrification, and reshoring. Nuclear power is seen as a proven, scalable solution for providing continuous, carbon-free baseload electricity, especially where data centers and critical facilities require reliable power.
- Favorable U.S. Policy Tailwinds: The bipartisan ADVANCE Act (July 2024) and Department of Energy (DOE) initiatives are accelerating licensing pathways, reducing fees, and providing substantial financial support for advanced reactors and microreactors. Over \$900 million in DOE funding is available for U.S.-made small modular reactors, with \$800 million earmarked for first-mover projects.
- Nuclea’s Morpheus Microreactor: The reactor is a lead-cooled, graphite-moderated design scalable from 3.5 MWe to 50 MWe, with significant inherent safety characteristics (high boiling point, low pressure, passive cooling, and no water/steam in the reactor). Nuclea’s proprietary, patent-pending annular fuel configuration aims to extend refueling cycles to five years, well beyond the industry norm. The modular reactor is designed for factory fabrication and transport via rail or road.
- Target Markets: Nuclea is focusing on deployments for data centers, defense/military installations, remote mining operations, and off-grid communities, all of whom are seeking alternatives to diesel and intermittent renewable power.
- Regulatory Pathways: Nuclea is advancing regulatory approval both in Canada (CNSC Vendor Design Review) and the United States (NRC Standard Design Approval), leveraging a capital-efficient approach.
Leadership and Governance Strength
Nuclea’s leadership team is comprised of experienced professionals with backgrounds in operations, engineering, nuclear safety, financial reporting, and public company governance. The Board includes a former Acting Deputy Assistant Secretary of the U.S. Department of Energy, senior mining and nuclear industry leaders, and regulatory experts from the Canadian and U.S. nuclear sectors, providing strong credentials to manage the complex development and regulatory environment of advanced nuclear technology.
Financial Advisory and Transaction Details
- Joseph Gunnar & Co., LLC is serving as exclusive financial advisor to Mangoceuticals for this transaction.
- The transaction is intended to give Nuclea access to public market capital and visibility, enabling faster advancement of its technology toward commercialization.
Potential Price-Sensitive Information for Shareholders
- Strategic Sector Entry: Mangoceuticals is making a major strategic pivot from its current focus on men’s health and telemedicine to the advanced nuclear sector—a move with potentially transformative implications for the Company’s valuation and risk profile.
- Share Issuance Cap: Due to Nasdaq rules, the transaction cannot be fully completed (and all rights realized by Nuclea shareholders) until Mangoceuticals receives stockholder and Nasdaq approval. Any delay or failure to secure these approvals could impact the transaction and share value.
- Exposure to Nuclear Technology Risks: The Morpheus microreactor is still in conceptual design; significant technology, regulatory, and capital risks remain. Failure to achieve technical or regulatory milestones could adversely affect valuation.
- Sector Tailwinds: Federal and state-level policy support for advanced nuclear, as well as surging AI and data center power demand, position Nuclea and Mangoceuticals to potentially benefit from substantial market and valuation uplift—should the company execute on its roadmap.
Additional Resources
Investors can view the full business combination agreement and related filings at www.SEC.gov. Nuclea Energy’s website offers further technical insights (https://www.nuclea.energy/), and Mangoceuticals continues to operate its telehealth business (www.MangoRx.com).
Disclaimer: This article is for informational purposes only and does not constitute investment advice, an offer, or solicitation to buy or sell securities. All forward-looking statements are subject to risks and uncertainties, including the risk that the transaction may not close, regulatory and shareholder approvals may not be obtained, and technology or market risks may impact future results. Investors are urged to review all filings with the SEC and consult with their financial advisors before making investment decisions.
